Denalitx and Biogen have registered the Phase 2b, randomized, double-blind, placebo-controlled (LUMA) study to determine the efficacy & safety of BIIB122 (LRRK2 inhibitor; DNL151) in 640 participants with #Parkinsons
Phase 2b study to determine the efficacy ... - Cure Parkinson's
Phase 2b study to determine the efficacy & safety of BIIB122 (LRRK2 inhibitor; DNL151) in 640 participants with Parkinsons
2 Replies
•
Key Inclusion criteria:.
.
.
. Screening genetic test results verifying the absence of a pathogenic leucine-rich repeat kinase 2 (LRRK2) variant.
it would be helpful if the clinical trials were done in more locations
Not what you're looking for?
You may also like...
Phase 3, the Lighthouse study, Biogen and Denali, LRRK2 inhibitor BIIB122; New clinical trial registered
inhibitor BIIB122; Phase 3, randomized, double-blind, placebo-controlled efficacy & safety study in...
Oral BIIB122/DNL151 Safely Lowers LRRK2 Activity in Phase 1 Trials
disease, according to results from two Phase 1 clinical studies....
Phase 4 study to evaluate efficacy of orally administrated Trehalose in individuals with idiopathic & LRRK2-associated Parkinsons
LRRK2-associated #Parkinsons
https://twitter.com/ScienceofPD/status/1522601517542514689...
AnnovisBio has initiated a 6-month Phase 3 study to evaluate 2 different doses Buntanetap (posiphen) in 450 participants with PD
initiated a 6-month, placebo-controlled, double-blind Phase 2 study to evaluate efficacy, safety, &...
The \"UP-study\" phase 2 trial of UDCA Co funded by Cure Parkinson's led by Prof Oliver Bandmann
\\"UP-study\\" phase 2 trial of UDCA Co funded by Cure Parkinson's led by Prof Oliver Bandmann...
Related Posts
Annovis Bio Announces Approval for EU Clinical Trial Sites for the Phase 3 Study of Buntanetap for the Treatment of Parkinson's Disease
Some \"Christmas Cheer\" we all need... Watch and enjoy!
Hope Biosciences Stem Cell Research Foundation- Get enrolled in the trial 
Big Fat Lie, Nutrition Policy | Nina Teicholz
BREAKTHROUGH THERAPY to treat PD!
